Abstract
Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that is involved in the folding, activation, and stabilization of numerous oncogenic proteins. It has become an attractive therapeutic target, especially for eradicating malignant cancers and overcoming chemotherapy resistance. The Hsp90 family in mammalian cells is composed of four major homologs: Hsp90α, Hsp90β, 94-kDa glucose-regulated protein (Grp94), and TNF receptor-associated protein 1 (Trap1). Hsp90α and Hsp90β are mainly localized in the cytoplasm, while Grp94 and Trap1 reside in the endoplasmic reticulum and the mitochondria, respectively. Additionally, some Hsp90 s are secreted from the cytoplasm, commonly called extracellular Hsp90. Interestingly, each Hsp90 isoform is localized in a particular organelle, possesses a unique biological function, and participates in various physiological and pathological processes. To inhibit the organelle-specific Hsp90 chaperone function, there have been significant efforts to accumulate Hsp90 inhibitors in particular cellular compartments. This review introduces current studies regarding the delivery of Hsp90 inhibitors to subcellular organelles, particularly to the extracellular matrix and the mitochondria, and discusses their biological insights and therapeutic implications.
Similar content being viewed by others
References
Aggarwal, S. 2010. Targeted cancer therapies. Nature Reviews Drug Discovery 9: 427–428.
Allan, R.K., D. Mok, B.K. Ward, and T. Ratajczak. 2006. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: Evidence that coumarin antibiotics disrupt Hsp90 dimerization. Journal of Biological Chemistry 281: 7161–7171.
Baines, C.P., R.A. Kaiser, N.H. Purcell, N.S. Blair, H. Osinska, M.A. Hambleton, E.W. Brunskill, M.R. Sayen, R.A. Gottlieb, G.W. Dorn, J. Robbins, and J.D. Molkentin. 2005. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434: 658–662.
Basso, E., L. Fante, J. Fowlkes, V. Petronilli, M.A. Forte, and P. Bernardi. 2005. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. Journal of Biological Chemistry 280: 18558–18561.
Becker, B., G. Multhoff, B. Farkas, P.J. Wild, M. Landthaler, W. Stolz, and T. Vogt. 2004. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Experimental Dermatology 13: 27–32.
Bohonowych, J.E., M.W. Hance, K.D. Nolan, M. Defee, C.H. Parsons, and J.S. Isaacs. 2014. Extracellular Hsp90 mediates an NF-kappaB dependent inflammatory stromal program: Implications for the prostate tumor microenvironment. Prostate 74: 395–407.
Boran, A.D., and R. Iyengar. 2010. Systems approaches to polypharmacology and drug discovery. Current Opinion in Drug Discovery & Development 13: 297–309.
Brough, P.A., W. Aherne, X. Barril, J. Borgognoni, K. Boxall, J.E. Cansfield, K.M. Cheung, I. Collins, N.G. Davies, M.J. Drysdale, B. Dymock, S.A. Eccles, H. Finch, A. Fink, A. Hayes, R. Howes, R.E. Hubbard, K. James, A.M. Jordan, A. Lockie, V. Martins, A. Massey, T.P. Matthews, E. McDonald, C.J. Northfield, L.H. Pearl, C. Prodromou, S. Ray, F.I. Raynaud, S.D. Roughley, S.Y. Sharp, A. Surgenor, D.L. Walmsley, P. Webb, M. Wood, P. Workman, and L. Wright. 2008. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. Journal of Medicinal Chemistry 51: 196–218.
Burgess, E.F., A.J. Ham, D.L. Tabb, D. Billheimer, B.J. Roth, S.S. Chang, M.S. Cookson, T.J. Hinton, K.L. Cheek, S. Hill, and J.A. Pietenpol. 2008. Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes. Proteomics Clinical Applications 2: 1223.
Chaffer, C.L., and R.A. Weinberg. 2011. A perspective on cancer cell metastasis. Science 331: 1559–1564.
Chen, B., W.H. Piel, L. Gui, E. Bruford, and A. Monteiro. 2005. The HSP90 family of genes in the human genome: Insights into their divergence and evolution. Genomics 86: 627–637.
Chen, C.F., Y. Chen, K. Dai, P.L. Chen, D.J. Riley, and W.H. Lee. 1996. A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock. Molecular and Cellular Biology 16: 4691–4699.
Chen, J.S., Y.M. Hsu, C.C. Chen, L.L. Chen, C.C. Lee, and T.S. Huang. 2010. Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression. Journal of Biological Chemistry 285: 25458–25466.
Costantino, E., F. Maddalena, S. Calise, A. Piscazzi, V. Tirino, A. Fersini, A. Ambrosi, V. Neri, F. Esposito, and M. Landriscina. 2009. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. Cancer Letters 279: 39–46.
Eustace, B.K., T. Sakurai, J.K. Stewart, D. Yimlamai, C. Unger, C. Zehetmeier, B. Lain, C. Torella, S.W. Henning, G. Beste, B.T. Scroggins, L. Neckers, L.L. Ilag, and D.G. Jay. 2004. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nature Cell Biology 6: 507–514.
Fang, W., X. Li, Q. Jiang, Z. Liu, H. Yang, S. Wang, S. Xie, Q. Liu, T. Liu, J. Huang, W. Xie, Z. Li, Y. Zhao, E. Wang, F.M. Marincola, and K. Yao. 2008. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. Journal of Translational Medicine 6: 32.
Felts, S.J., B.A. Owen, P. Nguyen, J. Trepel, D.B. Donner, and D.O. Toft. 2000. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. Journal of Biological Chemistry 275: 3305–3312.
Hance, M.W., K. Dole, U. Gopal, J.E. Bohonowych, A. Jezierska-Drutel, C.A. Neumann, H. Liu, I.P. Garraway, and J.S. Isaacs. 2012. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. Journal of Biological Chemistry 287: 37732–37744.
Jeong, C.H., H.B. Park, W.J. Jang, S.H. Jung, and Y.H. Seo. 2014. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC). Bioorganic & Medicinal Chemistry Letters 24: 224–227.
Kang, B.H., and D.C. Altieri. 2009. Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene 28: 3681–3688.
Kang, B.H., J. Plescia, T. Dohi, J. Rosa, S.J. Doxsey, and D.C. Altieri. 2007. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131: 257–270.
Kang, B.H., J. Plescia, H.Y. Song, M. Meli, G. Colombo, K. Beebe, B. Scroggins, L. Neckers, and D.C. Altieri. 2009. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. Journal of Clinical Investigation 119: 454–464.
Karagiannis, E.D., and A.S. Popel. 2006. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: Insights from a computational model. Journal of Theoretical Biology 238: 124–145.
Kusuma, B.R., A. Khandelwal, W. Gu, D. Brown, W. Liu, G. Vielhauer, J. Holzbeierlein, and B.S. Blagg. 2014. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry 22: 1441–1449.
Landriscina, M., M.R. Amoroso, A. Piscazzi, and F. Esposito. 2010. Heat shock proteins, cell survival and drug resistance: The mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. Gynecologic Oncology 117: 177–182.
Leav, I., J. Plescia, H.L. Goel, J. Li, Z. Jiang, R.J. Cohen, L.R. Languino, and D.C. Altieri. 2010. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. American Journal of Pathology 176: 393–401.
Lee, T., and Y.H. Seo. 2013. Targeting the hydrophobic region of Hsp90’s ATP binding pocket with novel 1,3,5-triazines. Bioorganic & Medicinal Chemistry Letters 23: 6427–6431.
Leskovar, A., H. Wegele, N.D. Werbeck, J. Buchner, and J. Reinstein. 2008. The ATPase cycle of the mitochondrial Hsp90 analog Trap1. Journal of Biological Chemistry 283: 11677–11688.
Li, W., D. Sahu, and F. Tsen. 2012a. Secreted heat shock protein-90 (Hsp90) in wound healing and cancer. Biochimica et Biophysica Acta 1823: 730–741.
Li, Y., G.E. Karagoz, Y.H. Seo, T. Zhang, Y. Jiang, Y. Yu, A.M. Duarte, S.J. Schwartz, R. Boelens, K. Carroll, S.G. Rudiger, and D. Sun. 2012b. Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90. Journal of Nutritional Biochemistry 23: 1617–1626.
Mahalingam, D., R. Swords, J.S. Carew, S.T. Nawrocki, K. Bhalla, and F.J. Giles. 2009. Targeting HSP90 for cancer therapy. British Journal of Cancer 100: 1523–1529.
Marcu, M.G., T.W. Schulte, and L. Neckers. 2000. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. Journal of the National Cancer Institute 92: 242–248.
Masuda, Y., G. Shima, T. Aiuchi, M. Horie, K. Hori, S. Nakajo, S. Kajimoto, T. Shibayama-Imazu, and K. Nakaya. 2004. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. Journal of Biological Chemistry 279: 42503–42515.
McCready, J., J.D. Sims, D. Chan, and D.G. Jay. 2010. Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: A role for plasminogen activation. BMC Cancer 10: 294.
McCready, J., D.S. Wong, J.A. Burlison, W. Ying, and D.G. Jay. 2014. An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein. Cancers (Basel) 6: 1031–1046.
Milane, L., M. Trivedi, A. Singh, M. Talekar, and M. Amiji. 2015. Mitochondrial biology, targets, and drug delivery. Journal of Controlled Release 207: 40–58.
Montesano Gesualdi, N., G. Chirico, G. Pirozzi, E. Costantino, M. Landriscina, and F. Esposito. 2007. Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress 10: 342–350.
Nakagawa, T., S. Shimizu, T. Watanabe, O. Yamaguchi, K. Otsu, H. Yamagata, H. Inohara, T. Kubo, and Y. Tsujimoto. 2005. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434: 652–658.
Patten, D.A., M. Germain, M.A. Kelly, and R.S. Slack. 2010. Reactive oxygen species: Stuck in the middle of neurodegeneration. Journal of Alzheimer’s Disease 20(Suppl 2): S357–S367.
Petrelli, A., and S. Giordano. 2008. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. Current Medicinal Chemistry 15: 422–432.
Pimienta, G., K.M. Herbert, and L. Regan. 2011. A compound that inhibits the HOP-Hsp90 complex formation and has unique killing effects in breast cancer cell lines. Molecular Pharmaceutics 8: 2252–2261.
Proia, D.A., and R.C. Bates. 2014. Ganetespib and HSP90: Translating preclinical hypotheses into clinical promise. Cancer Research 74: 1294–1300.
Rajendran, L., V. Udayar, and Z.V. Goodger. 2012. Lipid-anchored drugs for delivery into subcellular compartments. Trends in Pharmacological Sciences 33: 215–222.
Schleiff, E., and T. Becker. 2011. Common ground for protein translocation: Access control for mitochondria and chloroplasts. Nature Reviews Molecular Cell Biology 12: 48–59.
Segarra, M., C. Vilardell, K. Matsumoto, J. Esparza, E. Lozano, C. Serra-Pages, A. Urbano-Marquez, K.M. Yamada, and M.C. Cid. 2005. Dual function of focal adhesion kinase in regulating integrin-induced MMP-2 and MMP-9 release by human T lymphoid cells. FASEB Journal 19: 1875–1877.
Seo, Y.H. 2013. Discovery of licochalcone A as a natural product inhibitor of Hsp90 and its effect on gefitinib resistance in non-small cell lung cancer (NSCLC). Bulletin of the Korean Chemical Society 34: 1917–1920.
Seo, Y.H. 2015. Small molecule inhibitors to disrupt protein-protein interactions of heat shock protein 90 chaperone machinery. Journal of Cancer Prevention 20: 5–11.
Seo, Y.H., and S.Y. Park. 2014. Synthesis of flavokawain analogues and their anti-neoplastic effects on drug-resistant cancer cells through Hsp90 inhibition. Bullein of Korean Chemical Society 35: 1154–1158.
Shimamura, T., S.A. Perera, K.P. Foley, J. Sang, S.J. Rodig, T. Inoue, L. Chen, D. Li, J. Carretero, Y.C. Li, P. Sinha, C.D. Carey, C.L. Borgman, J.P. Jimenez, M. Meyerson, W. Ying, J. Barsoum, K.K. Wong, and G.I. Shapiro. 2012. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clinical Cancer Research 18: 4973–4985.
Sidera, K., M. Gaitanou, D. Stellas, R. Matsas, and E. Patsavoudi. 2008. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. Journal of Biological Chemistry 283: 2031–2041.
Sidera, K., and E. Patsavoudi. 2014. HSP90 inhibitors: Current development and potential in cancer therapy. Recent Patents on Anticancer Drug Discovery 9: 1–20.
Song, H.Y., J.D. Dunbar, Y.X. Zhang, D. Guo, and D.B. Donner. 1995. Identification of a protein with homology to hsp90 that binds the type 1 tumor necrosis factor receptor. Journal of Biological Chemistry 270: 3574–3581.
Sotgia, F., U.E. Martinez-Outschoorn, and M.P. Lisanti. 2011. Mitochondrial oxidative stress drives tumor progression and metastasis: Should we use antioxidants as a key component of cancer treatment and prevention? BMC Medicine 9: 62.
Sreedhar, A.S., E. Kalmar, P. Csermely, and Y.F. Shen. 2004. Hsp90 isoforms: Functions, expression and clinical importance. FEBS Letters 562: 11–15.
Stellas, D., A. El Hamidieh, and E. Patsavoudi. 2010. Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biology 11: 51.
Taipale, M., D.F. Jarosz, and S. Lindquist. 2010. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nature Reviews Molecular Cell Biology 11: 515–528.
Thuringer, D., A. Hammann, N. Benikhlef, E. Fourmaux, A. Bouchot, G. Wettstein, E. Solary, and C. Garrido. 2011. Transactivation of the epidermal growth factor receptor by heat shock protein 90 via Toll-like receptor 4 contributes to the migration of glioblastoma cells. Journal of Biological Chemistry 286: 3418–3428.
Tsutsumi, S., and L. Neckers. 2007. Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis. Cancer Science 98: 1536–1539.
Tsutsumi, S., B. Scroggins, F. Koga, M.J. Lee, J. Trepel, S. Felts, C. Carreras, and L. Neckers. 2008. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 27: 2478–2487.
Wang, X., X. Song, W. Zhuo, Y. Fu, H. Shi, Y. Liang, M. Tong, G. Chang, and Y. Luo. 2009. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proceedings of the National Academy of Sciences USA 106: 21288–21293.
Whitesell, L., and S.L. Lindquist. 2005. HSP90 and the chaperoning of cancer. Nature Reviews Cancer 5: 761–772.
Woodley, D.T., J. Fan, C.F. Cheng, Y. Li, M. Chen, G. Bu, and W. Li. 2009. Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90alpha autocrine signaling to promote keratinocyte migration. Journal of Cell Science 122: 1495–1498.
Wright, L., X. Barril, B. Dymock, L. Sheridan, A. Surgenor, M. Beswick, M. Drysdale, A. Collier, A. Massey, N. Davies, A. Fink, C. Fromont, W. Aherne, K. Boxall, S. Sharp, P. Workman, and R.E. Hubbard. 2004. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chemistry & Biology 11: 775–785.
Yi, F., and L. Regan. 2008. A novel class of small molecule inhibitors of Hsp90. ACS Chemical Biology 3: 645–654.
Zhang, T., A. Hamza, X. Cao, B. Wang, S. Yu, C.G. Zhan, and D. Sun. 2008. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Molecular Cancer Therapeutics 7: 162–170.
Acknowledgments
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2011-0023605).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest with any person or any organization.
Rights and permissions
About this article
Cite this article
Seo, Y.H. Organelle-specific Hsp90 inhibitors. Arch. Pharm. Res. 38, 1582–1590 (2015). https://doi.org/10.1007/s12272-015-0636-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-015-0636-1